Do analysts prefer MBRX or VCNX?

Moleculin Biotech presently has a consensus price target of $22.00, indicating a potential upside of 947.62%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Moleculin Biotech is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MBRX or VCNX more profitable?

Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% Vaccinex N/A N/A -383.58%

Which has stronger earnings and valuation, LIAN or VCNX?

Vaccinex has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Vaccinex $388K 7.91 -$20.25M -$48.27 N/A

Is LIAN or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Vaccinex N/A N/A -383.58%

Do analysts rate VCNX or GDTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, VCNX or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Vaccinex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaccinex $388K 7.91 -$20.25M -$48.27 N/A CytoMed Therapeutics $250K 45.85 -$3.10M N/A N/A

Is VCNX or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% CytoMed Therapeutics N/A N/A N/A

Do analysts rate KTTA or VCNX?

Pasithea Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 552.17%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Pasithea Therapeutics is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is KTTA or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Vaccinex N/A N/A -383.58%

Is FNCH or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Vaccinex N/A N/A -383.58%

Vaccinex (VCNX) Competitors

$1.18 0.00 (0.00%)

As of 07/21/2026 12:25 PM Eastern

Compare

VCNX vs. MBRX, LIAN, GDTC, KTTA, and FNCH

Should you buy Vaccinex stock or one of its competitors? MarketBeat compares Vaccinex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaccinex include Moleculin Biotech (MBRX), LianBio (LIAN), CytoMed Therapeutics (GDTC), Pasithea Therapeutics (KTTA), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry.

How does Vaccinex compare to Moleculin Biotech?

Moleculin Biotech (NASDAQ:MBRX) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Moleculin Biotech presently has a consensus price target of $22.00, indicating a potential upside of 947.62%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Moleculin Biotech is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Vaccinex	N/A	N/A	-383.58%

In the previous week, Moleculin Biotech had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for Moleculin Biotech and 0 mentions for Vaccinex. Moleculin Biotech's average media sentiment score of 0.67 beat Vaccinex's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Positive
Vaccinex	Neutral

Moleculin Biotech has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Vaccinex has higher revenue and earnings than Moleculin Biotech. Moleculin Biotech is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Vaccinex	$388K	7.91	-$20.25M	-$48.27	N/A

Summary

Moleculin Biotech beats Vaccinex on 8 of the 13 factors compared between the two stocks.

How does Vaccinex compare to LianBio?

LianBio (NASDAQ:LIAN) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Vaccinex has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Vaccinex	$388K	7.91	-$20.25M	-$48.27	N/A

Vaccinex's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Vaccinex	N/A	N/A	-383.58%

In the previous week, LianBio had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for LianBio and 0 mentions for Vaccinex. LianBio's average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Vaccinex	Neutral

LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

74.8% of LianBio shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Vaccinex beats LianBio on 6 of the 10 factors compared between the two stocks.

How does Vaccinex compare to CytoMed Therapeutics?

Vaccinex (NASDAQ:VCNX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

CytoMed Therapeutics has lower revenue, but higher earnings than Vaccinex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.91	-$20.25M	-$48.27	N/A
CytoMed Therapeutics	$250K	45.85	-$3.10M	N/A	N/A

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
CytoMed Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
CytoMed Therapeutics	N/A	N/A	N/A

Summary

Vaccinex and CytoMed Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Vaccinex compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Pasithea Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 552.17%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Pasithea Therapeutics is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for Pasithea Therapeutics and 0 mentions for Vaccinex. Pasithea Therapeutics' average media sentiment score of 0.50 beat Vaccinex's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Positive
Vaccinex	Neutral

Vaccinex's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Vaccinex	N/A	N/A	-383.58%

Vaccinex has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Vaccinex	$388K	7.91	-$20.25M	-$48.27	N/A

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 51.5% of Vaccinex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pasithea Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Summary

Pasithea Therapeutics beats Vaccinex on 8 of the 15 factors compared between the two stocks.

How does Vaccinex compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Vaccinex	Neutral

Vaccinex's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Vaccinex	N/A	N/A	-383.58%

Vaccinex has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Vaccinex	$388K	7.91	-$20.25M	-$48.27	N/A

Summary

Vaccinex beats Finch Therapeutics Group on 6 of the 9 factors compared between the two stocks.

Get Vaccinex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCNX vs. The Competition

Export

Metric	Vaccinex	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.07M	$946.57M	$7.01B	$12.68B
Dividend Yield	N/A	4.84%	2.67%	9.42%
P/E Ratio	-0.02	1.52	26.83	23.95
Price / Sales	7.91	110.62	576.15	115.11
Price / Cash	N/A	20.06	50.60	60.45
Price / Book	-0.46	8.60	10.56	6.16
Net Income	-$20.25M	-$3.23M	$3.60B	$331.73M
7 Day Performance	1.72%	-1.31%	-1.35%	-0.92%
1 Month Performance	42.24%	-4.37%	-0.29%	-2.23%
1 Year Performance	19.22%	27.53%	18.96%	14.79%

Vaccinex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCNX Vaccinex	N/A	$1.18 flat	N/A	+12.5%	$3.07M	$388K	N/A	40	Gap Down
MBRX Moleculin Biotech	2.2942 of 5 stars	$2.24 -3.0%	$22.00 +882.1%	-89.2%	$11.96M	N/A	N/A	20
LIAN LianBio	N/A	$0.11 flat	N/A	N/A	$11.95M	N/A	N/A	110
GDTC CytoMed Therapeutics	0.9091 of 5 stars	$1.00 -1.6%	N/A	-52.0%	$11.88M	$250K	N/A	N/A
KTTA Pasithea Therapeutics	3.389 of 5 stars	$0.47 -1.5%	$3.00 +536.9%	-36.1%	$11.75M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCNX) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccinex (VCNX) Competitors

VCNX vs. MBRX, LIAN, GDTC, KTTA, and FNCH

How does Vaccinex compare to Moleculin Biotech?

Summary

How does Vaccinex compare to LianBio?

Summary

How does Vaccinex compare to CytoMed Therapeutics?

Summary

How does Vaccinex compare to Pasithea Therapeutics?

Summary

How does Vaccinex compare to Finch Therapeutics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccinex (VCNX) Competitors

VCNX vs. MBRX, LIAN, GDTC, KTTA, and FNCH

How does Vaccinex compare to Moleculin Biotech?

Do analysts prefer MBRX or VCNX?

Do institutionals & insiders believe in MBRX or VCNX?

Is MBRX or VCNX more profitable?

Does the media prefer MBRX or VCNX?

Which has more volatility & risk, MBRX or VCNX?

Which has preferable valuation & earnings, MBRX or VCNX?

Summary

How does Vaccinex compare to LianBio?

Which has stronger earnings and valuation, LIAN or VCNX?

Is LIAN or VCNX more profitable?

Does the media refer more to LIAN or VCNX?

Which has more risk & volatility, LIAN or VCNX?

Do insiders & institutionals believe in LIAN or VCNX?

Summary

How does Vaccinex compare to CytoMed Therapeutics?

Which has higher valuation & earnings, VCNX or GDTC?

Do insiders & institutionals believe in VCNX or GDTC?

Which has more volatility & risk, VCNX or GDTC?

Does the media prefer VCNX or GDTC?

Do analysts rate VCNX or GDTC?

Is VCNX or GDTC more profitable?

Summary

How does Vaccinex compare to Pasithea Therapeutics?

Do analysts rate KTTA or VCNX?

Does the media refer more to KTTA or VCNX?

Is KTTA or VCNX more profitable?

Which has better valuation and earnings, KTTA or VCNX?

Do institutionals and insiders have more ownership in KTTA or VCNX?

Which has more risk and volatility, KTTA or VCNX?

Summary

How does Vaccinex compare to Finch Therapeutics Group?

Which has more risk and volatility, FNCH or VCNX?

Do insiders and institutionals hold more shares of FNCH or VCNX?

Does the media refer more to FNCH or VCNX?

Is FNCH or VCNX more profitable?

Which has better valuation and earnings, FNCH or VCNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools